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Proliferation of human hemopoietic cells in culture depends upon the presence
of exogenous growth factors such as granulocyte/macrophage colony-stimulating factor
(GM-CSF)' (1, 2), granulocyte CSF (G-CSF) (3, 4), and IL-3 (5), which exert their
mitogenic effects either singly or in synergy with IL-1 (6-9) or IL-6 (10-13) . Nega-
tive growth control in the hemopoietic system is, however, less understood . Recent
studies indicated that transforming growth factor0(TGF0) (14, 15), TNFa(16-21),
and interferons (22, 23) may restrain hemopoietic cell proliferation after binding
to specific cell surface receptors .
Autocrine stimulation and absence of negative growth control may represent pos-
sible events leading to cancer cell proliferation . There is accumulating evidence to
support the concept of autocrine stimulation in cancer (reviewed in reference 24).
To this effect, it has been shown that theleukemic cells ofacutemyeloblastic leukemia
(AML) are capable of autostimulation when cultured at high cell density (25) . The
importance of negative growth control in normal cell proliferation and neoplasia
has recently been more widely acknowledged . Thus, Kimchi et al . (26) have shown
that retinoblastomas lack TGF,6 receptors and growth inhibitory responses while
normal fetal retina are sensitive to the antimitogenic effects of TGF-0 . We inves-
tigated the possibility of whetherAML blasts may also have altered responsiveness
to the growth inhibitory cytokines . Ourprevious work (27) indicated thatAML blasts
are sensitive to the inhibitory effects ofTGF0 . Here, it is shown that TNFU, an-
other growth inhibitory cytokine, fails to support growth arrest under specific con-
ditions . Thus,TNFa enhances the cell density-dependent and GM-CSFdependent
proliferation ofAMLblasts while it antagonizes the mitogenic effects ofG-CSF and
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IL-3 on the same cells. TNFa, therefore, acts as a bimodulator ofAML cell prolifer-
ation, with the unique capacity to either support or inhibit cell proliferation depending
on the growth signaling context, while on normal hemopoietic progenitors, TNF-a
appears to support only growth arrest.
Materials and Methods
Source ofCells and Growth Factors.
￿
AML blasts were isolated by centrifugation ofperipheral
blood cells on a Ficoll-Hypaque gradient (Pharmacia Fine Chemicals, Uppsala, Sweden) .
The cells were cryopreserved in Iscove's modified Dulbeccds medium (IMDM) (Gibco Labora-
tories, Grand Island, NY) containing 10% DMSO and 90% FCS (Gibco Laboratories) and
stored in liquid nitrogen until use. A programmed freezing rate of 1°/min ensures a 90%
recovery in viable cells upon thawing. Patient data are shown in Table I. The numbering
system is the same as in references 6 and 10. Normal bone marrow cells were obtained from
patients undergoing hip replacement (Dr. C. Godin, Hotel Dieu Hospital, Montreal) and
separated on a Ficoll-Hypaque gradient.
Purified recombinant TNFa was obtained from Amgen Biologicals (Arlington Heights,
CA). A concentration of60 pM corresponds to 1 ng/ml or 10 U/ml. rG-CSF, purified rIL-3,
rIL-6, and rGM-CSF were kindly provided by Drs. G. G. Wong and S. C. Clark (Genetics
Institute, Cambridge, MS); the specific activity of rGM-CSF was 8 x 106 U/mg. A protein
concentration of 100 pM (2 .5 ng/ml) corresponds to a biological activity of 20 U/ml. Purified
HL-la and the neutralizing antibody against IL-1/3 were generous gifts from Dr. A. Shaw
(Biogen, Geneva, Switzerland), and rErythropoietin was from Dr. D. Hankins (Armed Force
Radiobiological Institute, Bethesda, MD). Serum-freeconditioned medium from the cell line
5637 (5637 CM) was harvested 1 wk after confluence as detailed previously (6).
Culture Conditions.
￿
Culture conditions were chosen in order to minimize colony forma-
tion in the absence of growth factors. (a) AML blasts were plated at a concentration of
7,000/well, unless otherwise stated, in 100 p.l of IMDM (Gibco Laboratories) viscified with
methylcellulose (Fluka, Switzerland), and supplemented with 10% FCS (Gibco Laborato-
ries) as described previously (6). KG-1 cells, obtained from the American Type Culture Col-
lection (Rockville, MD) were cultured under the same conditions, except that the cell con-
centration was 1,000/well. (b) Nonadherent normal bone marrow cells were plated in the same
culture medium as above supplemented with BSA and human transferrin (Behring Diag-
nostics, San Diego, CA) at a concentration of 5 x 104 cells/ml as detailed elsewhere (6).
Thymidine Suicide Determinations.
￿
The number of AML clonogenic cells that was in cycle
in response to growth factors was determined by an adaption of the thymidine suicide tech-
nique(28), as described by Pebusque et al. (29). Briefly, cellswere exposed to TNFa or GM-
CSF for 16 h, washed twice, and exposed to [3H]thymidine (Amersham Corp., Arlington
Heights, IL) (25 Ci/mmol, sp act; 200 uCi/ml) for 20 min. The reaction was stopped by
the addition of cold thymidine and the cells were washed twice in medium containing FCS
before plating. Control cells were exposed to the wholeprocedure without radioactive thymidine.
Northern Blots andHybridization Conditions.
￿
RNA was extracted in the presence ofguanidium
isothiocyanate (Bethesda Research Laboratories, Gaithersburg, MD), subjected to electropho-
resis in 1% agarose in the presence of glyoxal (30), and transferred to a Nytran membrane
(Schleicher & Schuell, Inc., Keene, NH). The probe was the Pst-1 fragment of the human
IL-10 cDNA (6) and was labeled by random priming with the Klenow (31) to a specific ac-
tivity of 3 x 108 cpm/ug. Prehybridization and hybridization were done in the presence of




The IL-1/3 ELISA kit was from Cistron Biotechnology (Pinebrook, NJ).
All reactions were carried out at room temperature. The specificity of the assay was confirmed
by the lack of reactivity with TNFa, GM-CSF, and IL-6. Conditioned media from AML
blasts were harvested 24 h afterinitiation of the cultures either in the presence of GM-CSF
alone or both GM-CSF and TNFa at the indicated concentrations.The proportion of blasts is expressed as a percentage of total nucleated cells
in the peripheral blood.
Sample AML 10 contains, in addition, 35% immature granulocytic cells.
Results
When tested in primary cultures of AML blasts from different patients, TNFa
stimulated colony formation in synergy with GM-CSF (Fig. 1 A). As documented
elsewhere (32-34), the level ofstimulation observed in the presence ofGM-CSF alone
(intersects with they-axes) was suboptimal with wide patient to patient variations.
Addition of TNFa at increasing concentrations nearly reconstituted or, in two in-
stances, doubled the maximal level of stimulation attained with our standard condi-
tioned medium 5637, which contained a mixture of GM-CSF, G-CSF, and IL-1,
and was so far optimal in supporting the growth of AML clonogenic cells (6). The
synergy with GM-CSF occurred at concentrations of TNFa as low as 6-60 pM,
in the same range as the dissociation constant of TNFa reported for AML blasts
and myeloblastic cell lines (29-94 pM ; reference 21). Further, these concentrations
required for stimulation of AML blasts were in the same range as that described
for other hemopoietic growth factors. No inhibitoryeffect was observed, even at con-
centrations that were 1,000-fold in excess (60 nM). Nevertheless, in five of eight pa-
TABLE I
Clinical Data on the AML Patients Included in the Study






Effects of TNF-a on AML blast
clonogenic cells and normal granulocyte/mono-
cyte precursors in the presence of GM-CSF.
(A) Purified rGM-CSF was added at a final
concentration of40 pM to cultures containing
the indicated concentrations ofrTNFa. Data
shown represent the mean of five replicate cul-
tures. Values were normalized to the colony
counts obtained in the presence of our stan-
dard conditioned medium 5637: 44 (AML 1);
35 (AML 2); 56 (AML 3); 33 (AML 5); 222
(AML 6); 70 (AML 8); and 143 (AML 9).
There was no colony formation in the absence
of exogenous growth factors. (B) Growth
factors were added at the same concentrations
as above. Colony counts in the presence of
5637-CM were 37 (KG-1) and 72 (CFU-GM).
Colony counts in the absence ofgrowth factors
were 4 (KG-1) and 0 (CFU-GM).
Patient FAB classification Percent blasts
AML 1 M2 68
AML 2 M4 60
AML 3 M56 38
AML 5 M3 90
AML 6 M1 40
AML 8 M2 80
AML 9 M4 85
AML 10' M2 4918
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tient samples, the degree of synergywith GM-CSF was lowerat this high concentra-
tion of TNFa .
In contrast to its growth-promoting effects on AML clonogenic cells, TNFa an-
tagonized the mitogenic effects ofpurified GM-CSF on normal granulo-monopoietic
progenitors (CFU-GM) and on the human leukemic cell line KG-1 (Fig. 1 B), in
the same concentration range as documented by others (18-20). These studies (18,
20) also reported an inhibitory effect of TNF-a on AML or CML patient cells cul-
tured in the presence of crude conditioned media from mitogen-stimulated leuko-
cytes or cell lines that contained a mixture of growth factors (1-13). We have ob-
served the same inhibition when TNF-a was added to cultures of AML blasts
stimulated with either 5637-CM, IL-3, or G-CSF (Table II). However, TNFa does
not affect cell proliferation in the presence of IL-la (Table II). Cultures with IL-la
were done at higher cell concentration, as we have shown previously that IL-la can
support blast colony formation by itself, only at higher cell concentration (6).
It hasbeen reported by Nara and McCulloch (25) that AML blasts plated at higher
cell concentration arecapable of autocrine stimulation. Undersuch conditions, TNFa
supported colony formation from AML blasts without further addition of other ex-
ogenous growth factors (Table II and Fig. 2 A). Taken together, the data suggested
that TNF-a promoted growth ofAMLclonogenic cells in thepresence ofeither GM-
CSF or an endogenous source of growth stimulators.
To determine whetherTNFce recruits the same population ofprogenitors as GM-
CSF or a different population, AML blasts were exposed to GM-CSF, followed by
thymidine suicide, a procedure based on the lethal incorporation of [3H]TdR by
cells undergoing DNA synthesis. Surviving cells were plated in the presence of ei-
ther GM-CSF, TNF-a, or 5637-CM and compared with cells that have not been
exposed to thymidine (Table III). Thymidine suicide of cellspre-incubated with GM-
CSF resulted in acomplete suppression ofthe population ofcells responsive to TNFa
and GM-CSF, while a significantly high number of clonogenic cells stimulated by
5637-CM survived the exposure to radioactive thymidine. Comparable results were
observed when cellswere pre-exposed to TNFa insteadofGM-CSF (data not shown).
TABLE II
TNF-a Inhibits the IL-3- and G-CSF-dependent
Growth of AML Clonogenic Cells
Growth factor concentrations were optimal on separate dose response curves:
TNF-a (600 pM), IL-3 (50 U/ml), and G-CSF (50 U/ml). Data are mean of
five replicate cultures, with AML 6 at 7,000 cells/well and AML 8 at 104






AML 6* None 0 17 ± 4
IL-3 47 t 5 8 ± 3
G-CSF 24 ± 5 0
5637 CM 77 t 1 46 ± 3
AML 81 None 9 ± 3 51 ± 6
GM-CSF 45 ± 8 79 t 6
IL-1 54 + 7 69 ± 10300
200 z
0 U





The data suggested that TNFa supported cell proliferation in the subpopulation
of progenitors that also appeared to be responsive to GM-CSF. The difference be-
tween the surviving fractions ofcells stimulated with 5637-CM and GM-CSF could
be attributed to other growth factors present in the conditioned medium, such as
G-CSF, which has been shown to act on different target cells than GM-CSF (29) .
We further investigated the question of whether the stimulatory effects of GM-
CSF and TNFct were additive or synergistic. The two growth factors were added
either singly or in combination to cultures containing different cell numbers (Fig.
2 A). At the lowest cell concentration, either growth factor alone failed to support
significant colony formation; however, high numbers of colonies were observed in
the presence of both GM-CSF and TNFa. Further, when TNF-a was added at an
optimal concentration to cultures containing varying concentrations of GM-CSF,
the response of AML clonogenic cells to GM-CSF was significantly enhanced (Fig.
TABLE III
Growth ofAML Clonogenic Cells after Exposure to GM-CSF
in Suspension Culture Followed by Thymidine Suicide
FIGURE 2.
￿
Synergistic effects of TNF-a and GM-CSF in the stimulation of AML blast clono-
genic cells. (A) Effects of growth factors at different cell concentrations. Growth factors were TNF-a
(600 pM) and GM-CSF (100 pM). Cells were from AML 6. (B) GM-CSF titration in the pres-
ence of TNF-a (600 pM). The cell concentration was 104/well (AML 6).
Cells (AML 8) were exposed to GM-CSF (100 pM) in suspension cultures for
16 h, at a concentration of 2 x 10' cells/ml. The cells were then washed and
exposed to [ SH]TdR before plating. Methyl cellulose cultures were done at 104
cells/well, with either 5637 CM (10%), or TNF-a (600 pM) or rGM-CSF (100
pM). Data shown arc typical of two distinct experiments.







5637 CM 126 ± 20 75 ± 5
TNF-a 43 + 4 0
GM-CSF 33 + 3 0
TNF-a + GM-CSF 124 + 14 5 + 320
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2 B) . For example, at a suboptimal concentration of GM-CSF (4 pM), only a few
colonies were observed . However, when both growth factors were present, there was
a 40-fold increase in the number of colonies . Taken together, the results indicated
that the stimulatory effects of the two cytokines onAML clonogenic cells are syner-
gistic, rather than additive .
TNF-a has been reported to modulate the production of IL-1 by monocytes (35) .
In parallel, AML blasts have been shown to express IL-10 mRNA (36) and to re-
spond to the synergistic effects of exogenously added IL-1 and GM-CSF (6) . We
therefore addressed the question of whether the observed synergy between TNF-a
and GM-CSF could be attributed to an endogenous production of IL-10 by AML
cells . Cultures were done at higher cell concentration (10 4/ml) to favor cell interac-
FIGURC 3 .
￿
Effects of the neu-
tralizing antibody against IL-10
on the growth of blast clono-
genic cells in the presence of
TNF-a and GM-CSF. Cultures
were done at 104 cells/well . Data
shown in the lower panel are
typical ofindependent cultures
with AML 8 and AML 10 ; re-
sults are shown for 10 (concen-
trations of growth factors as in
Fig . 2 A) . Colony counts in the
absence of growth factors were
0 (AML 9) and 25 (AML 10) ;
and in the presence of TNF-a
alone were 0 (AML 9) and 47
(AML 10) . (Inset) Expression of
IL-10 mRNA by AML blasts .
Total RNA (20 Wg/lane) was
denatured and analyzed by
RNA blotting with the IL-10
cDNA probe . Shown are RNA
from AML 6, AML 10, AML
9, and 5637 cells (Q .HOANG ET AL.
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tion and endogenous growth factor production (Fig. 3). Addition of anti-IL-10 to
such cultures reduced the synergistic action ofTNFa and GM-CSF on AML blasts
with a dose-dependent effect. The reduction in colony count was not due to a
nonspecific toxicity of the antibody, since it does not affect the synergistic stimula-
tion of blast progenitors by G-CSF, GM-CSF, and IL-6 (Table IV).
There was, however, a marked difference between the three samples tested, AML
8, 9, and 10 (Fig. 3). AML 8 and 10 behaved similarly, in that addition of anti-IL-10
to cultures containing both GM-CSF and TNFa brought colony counts to the levels
of stimulation observed with GM-CSF alone. In contrast, there was only a partial
neutralization of the synergistic effects of the two growth factors on AML 9 cells
upon addition of anti-IL-1(3. The endogenous production of IL-10 was confirmed
by Northern blotting analyses, revealing the presence of IL-1,6 mRNA in the same
cell populations (Fig. 3 inset). As the intensities of the IL-1/3 bands are comparable
between AML 9 and 10, the levels of IL-1a produced by the two cell types may also
be comparable. Consequently, the difference between a complete and partial neu-
tralization effect of anti-IL-10 on the two cell types may not be due to differences
in IL-1 concentrations, but may perhaps be attributed to the involvement of addi-
tional mechanisms in the synergy between TNFa and GM-CSF in the case ofAML
9 blasts .
The production of IL-1/3 by AML blasts was confirmed by ELISA. No produc-
tion was detectable when cells were cultured in GM-CSF alone. However, in the
presence of TNF-a and GM-CSF, the production of IL-10 was in the order of 100
pg/ml (Table V). Taken together, our data suggest that the growth-promoting effects
of TNFa on AML blasts could be attributed in part to induction of an endogenous
TABLE IV
The Antibody against IL-1,6 Does not Affect the Synergistic Effects of
G-CSF and GM-CSF or IL-6 with G- and GM-CSF on AML Blasts
The anti-IL-10 was a sheep antibody raised against purified IL-1/3. At a con-
centration of 1 :10,000, it neutralized 50 pM ofIL-1,Q. Cultures ofAML blasts
were stimulated with optimal concentrations of growth factors. 75 pM (GM-CSF),
10 U/ml (G-CSF), 750 pM (IL-6), and 75 pM (IL-3).
Antibody Colony
Cells Growth factor added dilutions counts
AML 10 0 - 0
GM-CSF - 35 + 5
G-CSF - 2 + 1
GM-CSF + G-CSF - 57 + 3
GM-CSF + G-CSF 1 :8,100 68 ± 10
GM-CSF + G-CSF 1:2,700 65 ± 2
GM-CSF + G-CSF 1:900 59 + 8
GM-CSF + G-CSF 1:300 60 + 1
GM-CSF + G-CSF 1:100 65 + 15
AML 8 GM-CSF + G-CSF - 91 t 7
GM-CSF + G-CSF + IL-6 - 140 1 4
GM-CSF + G-CSF + IL-6 1 :100 136 f 6
IL-3 - 83 + 11
IL-3 1:100 78 f 12 2
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TABLE V
Production of IL-1,d by AML Blasts Determined by ELISA
The IL-1/3 ELISA was performed as described in Materials and Methods. Growth
factors were diluted in IMDM/10% FCS. Culture medium with no added growth
factor served as a negative control. Cells were from AML 9 stimulated with GM-
CSF (AML-CM 2) or TNF-a and GM-CSF (AML-CM 1) at the following con-
centrations : 80 pM (2 ng/ml, GM-CSF) and 240 pM (4 ng/ml, TNF-a).
production of IL-1(3. Further, TNFa did not significantly affect colony formation
in the presence of exogenously added IL-1 (Table II), suggesting that the two mole-
cules may have overlapping growth signaling pathways. In fact, it has been shown
that TNF-a, IL-la, and IL-1(3 induce the production of the same enzymes while
other pleitropic cytokines such as interferons and TGF-(3 behave differently (37).
Discussion
The presence of a single class of high affinity receptors for TNF-a on normal
hemopoietic cells, AML blasts, and human leukemic cell lines was reported recently
by Munker et al. (21). Unlike TGF(3 on retinoblastomas, lack of a growth inhibitory
response to TNFa was not related to the absence of TNFa receptors on several
TNFa-resistant cell lines such as K562. These results would suggest that the pecu-
liar response ofAML blasts to TNF-a and GM-CSF, as compared with normal cells,
is probably not due to differences in TNF-a receptors.
The mechanism underlying the synergistic stimulation of AML blasts by TNF-a
and GM-CSF may be complex. Our results suggest that it can be explained in part
by an induction of endogenous IL-1(3 production by the cells. However, patient sample
AML 5 was refractory to exogenously added IL-1, as observed in our previous study
(6), while the other patient samples are responsive. The synergy between GM-CSF
and TNF-a in the case of AML 5 is likely due to other mechanisms . Further, there
was only a partial neutralization of the synergy between TNFFa and GM-CSF in
the stimulation of AML 9 blasts upon addition ofanti-IL-1(3, suggesting the involve-
ment of additional mechanisms. Thus, at the cellular level, TNFa appears to re-













AML 9-conditioned media AML-CM 1 1 :3 0.150
Undiluted 0.494
AML-CM 2 1:3 0.041
Undiluted 0.053HOANG ET AL.
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ofthe cells to GM-CSF. As receptor modulation has been reported in other systems
toexplain the synergistic effectsbetween growth factors (38), itis possible that TNFa
exerts amodulationofGM-CSF receptors. In thecase ofAMLblasts, however, TNFa
enhanced the stimulatoryeffects ofGM-CSFwhileantagonizing that ofIL-3, a growth
factor that appears to share common biologicproperties with GM-CSF and has the
unique capacity to compete for GM-CSF binding to target cells (39). It is possible
that the molecularmechanism ofsynergy with GM-CSF is morecomplex thanmere
receptor modulation, involving perhaps post-receptor events.
TNF-a in most biological systems acts as a growth inhibitory cytokine. However,
a growth-enhancing effect was observed on fibroblasts and epithelial cells (reviewed
in reference 40), and agrowth-stimulating effect was observed onthe malignant cells
of chronic B cell leukemias (41). On AML blasts, TNFa can either support or in-
hibit cell proliferation, depending on the other growth factors present. Thus, much
in the same way as TGF0 (40), TNF-a appears to be multifunctional, depending
on the cell type and the growth-signaling context. We have not directly addressed
the question ofcell type responding to TNF in the present study. Nonetheless, sev-
eral observations suggest that blast clonogenic cells are ableto respond to the growth-
promoting effects ofTNFa. First, GM-CSF and TNF appear to recruit the same
population ofcells. Second, AML blasts havebeen shown to express TNFareceptors
(21) with dissociation constants that are in the same range as the concentrations re-
quired for half-maximal stimulation of blast colony formation. Taken together, the
data suggest that TNFa canefficientlyfunction asabimodulator ofAMLcellprolifer-
ation. It will be important, however, to document by additional cell separation tech-
niques whether an accessory cell function is required for the stimulation of AML
blasts by TNFa.
Whether thepeculiar response ofAML blasts to TNFu and GM-CSFwould bear
some physiological significance is a matter ofdebate. So far, analysis ofAML blasts
at the cellular and molecular levels and ofclinical outcome in AML have disclosed
significant patient to patient heterogeneity (42). Our previous studies on GM-CSF,
IL-1, and IL-6 responsiveness also revealed significant variations (6, 10). For example,
AML 1-4 responded to IL-1 while AML 5 was refractory (6). Similarly, AML 1,
2, and 7 were IL-6 responsive, while AML 3 and 5 were not (10). However, all these
AML samples displayed a comparable response to the combined stimulatory effects
ofGM-CSF and TNFa. In striking contrast with the other biological properties,
theuniformity ofresponse toTNFaand GM-CSF inthe eight AML samples studied
so far would suggest that this property may bear some physiological significance.
Ofinterest, TNFais capableofsupporting colony formation in the absence ofother
growth factors when tested at high cell density, that is, under conditions that favor
autocrine stimulation. It is possible that the synergistic effects ofTNF-a with an
autocrine growth signal would allow thecells to escape from negative regulation and
acquire a proliferative advantage.
Our study also brings out the importance ofprimary cultures in studying some
intrinsic biologic properties ofleukemic cells. Thus, the GM-CSF responsive cell
line KG-1 was inhibited by TNFa (11), indicating that it failed to exhibit the same
responseto TNFa as freshly isolatedAMLblasts. The availability oflarge numbers
of cells that are not selected by culture conditions provides a unique opportunity
to study mechanisms involved in both normal and leukemic cell proliferation.24
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Summary
TNF-a has been shown to antagonize the proliferative effects of growth factors
present in crude conditioned media from PHA-stimulated leukocytes or cell lines
on the clonogenic cellsof acute myeloblastic leukemia (AML) (19, 21). In the present
study, we investigated the responses of AML blasts to TNFa in the presence ofdefined
growth factors (recombinant granulocyte/macrophage-CSF [rGM-CSF], recombinant
granulocyte-CSF [rG-CSF], rIL-3, and rIL-1) and under conditions described for
autocrine stimulation (32). While TNFa antagonized the stimulatory effects ofG-CSF
and IL-3 on blast progenitors, TNFa did not affect blast colony formation in the
presence of IL-1. Unexpectedly, TNF-a significantly enhanced blast proliferation
in the presence of GM-CSF. Further, TNFa also acted synergistically with an en-
dogenous source of growth stimulatory signal to promote proliferation ofblast clono-
genic cells. Thus, on human leukemic cells, TNFa appears to be a molecule that
is at least bifunctional, having the ability to either support or inhibit cell prolifera-
tion, depending on the other growth factors present. It is postulated that the prolifer-
ative response of blast progenitors to TNFa under conditions that favor autocrine
stimulation may represent one property that allows the cells to escape from negative
regulation and proliferate in AML .
The authors wish to thank Drs. A. Lacroix and R. Sekaly for critical reading of the manu-
script and Ms. F. De Coste for most careful typing.
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